Клиническое наблюдение применения тоцилизумаба при рефрактерном системном ювенильном артрите с поражением легких и синдромом активации макрофагов
https://doi.org/10.14412/1995-4484-2015-446-451
Аннотация
Представлено клиническое наблюдение применения тоцилизумаба (ТЦЗ) у пациента с рефрактерным системным ювенильным артритом, особенности терапевтического ответа в реальной клинической практике, рассмотрены аспекты индивидуальной безопасности ТЦЗ при развитии синдрома активации макрофагов и проведения сопутствующей терапии
Об авторах
М. И. КаледаРоссия
И. П. Никишина
Россия
С. Р. Родионовская
Россия
Список литературы
1. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7(7):416–26. doi: 10.1038/nrrheum.2011.68
2. Rabinovich CE. Juvenile Rheumatoid Arthritis. Medscapee Medicine Rheumatology. Available from: http://emedicine.medscape. com/article/1007276-overview. Updated June 1, 2010. Accessed March 1, 2010.
3. Fujikawa S, Okuni M. Clinical analysis of 570 cases with juvenile rheumatoid arthritis: results of nationwide retrospective survey in Japan. Acta Paed Jpn. 1997;39(2):245–9. doi: 10.1111/j.1442- 200X.1997.tb03593.x
4. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78. doi: 10.1016/S0140-6736(07)60363-8
5. Алексеева ЕИ, Литвицкий ПФ. Ювенильный ревматоидный артрит. Руководство для врачей, преподавателей, научных сотрудников. Москва: ВЕДИ; 2007. 359 с. [Alekseeva EI, Litvitskii PF. Yuvenil'nyi revmatoidnyi artrit. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov [Juvenile rheumatoid arthritis. Guidelines for doctors, teachers, scientists]. Moscow: VEDI; 2007. 359 p.].
6. Behrens EM, Beukelman T, Gallo L, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol. 2008;35(2):343–8.
7. Cassidy JT. Juvenile rheumatoid arthritis. In: Cassidy JT, Petty RE, editors. Textbook of pediatric rheumatology. 4th ed. Philadelphia: W.B. Saunders Company; 2001:218–322.
8. Baum J, Alekseev LS, Brewer EJ Jr. Juvenile rheumatoid arthritis. A comparison of patients from the USSR and USA. Arthritis Rheum. 1980;23(9):977–84. doi: 10.1002/art.1780230903
9. Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006;54(5):1595–601. doi: 10.1002/art.21774
10. Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27(2):491–6.
11. Grom AA, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996;129:630–2. doi: 10.1016/S0022-3476(96)70140-3
12. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007 May; 34(5):1133–8. Epub 2007 Mar 1.
13. Davi S, Consolaro A, Guseinova D, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011;38:764–8. doi: http://dx.doi.org/10.3899/jrheum.100996
14. Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin N Am. 1991;17(4):891–905.
15. Still GF. On a form of chronic joint disease in children. 1896. Clin Orthop Relat Res. 1990 Oct;259:4–10.
16. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol. 2006;2(1):28–34. doi: 10.1038/ncprheum0084
17. Yokota S, Miyamae T, Imagawa T, et al. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allerg Immunol. 2005;28:231–8. doi: 10.1385/CRIAI:28:3:231
18. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006. doi: 10.1016/S0140-6736(08)60454-7
19. Yokota S, Imagawa T, Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic- onset juvenile idiopathic arthritis [SAT0536]. Ann Rheum Dis. 2009;68 Suppl 3:715.
20. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–8. doi: 10.1186/ar1826
21. De Benedetti F, Brunner H, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95. doi: 10.1056/NEJMoa1112802
22. Kumar S, Kunhiraman DS, Rajam L. Application of the Yamaguchi criteria for classification of «suspected» systemic juvenile idiopathic arthritis (sJIA). Ped Rheumatol. 2012;10:40. doi: 10.1186/1546-0096-10-40
23. Reiff A. Treatment of systemic juvenile idiopathic arthritis with tocilizumab – the role of anti-interleukin-6 therapy after a decade of treatment. Biol Ther. 2012;2:1. doi: 10.1007/s13554-012-0001-6
24. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.
25. doi: 10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R 25. Papadopoulou C, Kostik M, Gonzalez-Fernandez MI, et al. Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. Arthritis Care Res (Hoboken). 2013 Jul;65(7):1112–20. doi: 10.1002/acr.21947
26. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598–604. doi: 10.1016/j.jpeds.2004.12.016
27. Isaacs JD, Harari O, Kobold U, et al. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther. 2013;15(6):R204. doi: 10.1186/ar4397
28. Aoki C, Inaba Y, Choe H, et al. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. J Rheumatol. 2014;41:1171–7. doi: 10.3899/jrheum.130924
Рецензия
Для цитирования:
Каледа М.И., Никишина И.П., Родионовская С.Р. Клиническое наблюдение применения тоцилизумаба при рефрактерном системном ювенильном артрите с поражением легких и синдромом активации макрофагов. Научно-практическая ревматология. 2015;53(4):446-451. https://doi.org/10.14412/1995-4484-2015-446-451
For citation:
Kaleda M.I., Nikishina I.P., Rodionovskaya S.R. A CASE REPORT OF THE USE TOCILIZUMAB IN REFRACTORY SYSTEMIC JUVENILE ARTHRITIS WITH PULMONARY INVOLVEMENT AND MACROPHAGE ACTIVATION SYNDROME. Rheumatology Science and Practice. 2015;53(4):446-451. (In Russ.) https://doi.org/10.14412/1995-4484-2015-446-451